Autres langues Intensity Therapeutics, Inc.

Actions

INTS

US45828J1034

Temps Différé Nasdaq Autres places de cotation 18:36:55 10/05/2024			Varia. 5j.	Varia. 1 janv.
4,053 ^USD	+7,78%		+4,99%	-52,71%

17:22	Intensity Therapeutics collabore avec le Groupe suisse de recherche clinique pour un essai sur le cancer du sein	MT
19/04	Intensity Therapeutics, Inc. annonce la démission de Daniel Donovan du comité d'audit du conseil d'administration	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Intensity Therapeutics Collaborates With Swiss Group on Clinical Research for Breast Cancer Trial	17:22
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate	14:02
Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update	09/05
Intensity Therapeutics : Failure to Satisfy Listing Rule - Form 8-K	19/04
Intensity Therapeutics, Inc. Announces Resignation of Daniel Donovan from Audit Committee of the Board of Directors	19/04
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024	02/04
Portage biotech completes monetization of intensity therapeutics shares	27/03
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares	26/03
Intensity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024	14/03
Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference	21/02
Intensity Therapeutics Gets FDA Green Light for Phase 3 Study	03/01
Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program	03/01
Certain Common Stock of Intensity Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 26-DEC-2023.	26/12
Certain Warrants of Intensity Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 26-DEC-2023.	26/12
Certain Stock Options of Intensity Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 26-DEC-2023.	26/12
Intensity Therapeutics Names Joseph Talamo as Finance Chief	12/12
Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer	12/12
Intensity Therapeutics, Inc. Announces Appointment of Joseph Talamo as Chief Financial Officer	12/12
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS	11/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Intensity Therapeutics, Inc.

Actions

INTS

US45828J1034

Autres langues

Filtres